Table 1 displays the statistics of clinical features. There were significant differences in tumor size, ER and HER2 status between the high Ki-67 group and the low Ki-67 group in the training set and the test set (p < 0.05). Additionally, PR status differed significantly in the training set (p < 0.05). However, no notable differences were found in age, location of mass, menstrual status, and lymph node metastasis in either the training set or the test set (p > 0.05). Here, MKI67 is linked to metastatic malignant neoplasm in the lymph nodes.